• PIN27 COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS

    Nov 1, 2008, 00:00

  • PIH10 THE COST EFFECTIVENESS OF SCHEDULED MAINTENANCE TREATMENT WITH INFLIXIMAB AMONG PAEDIATRIC PATIENTS WITH CROHNS DISEASE IN SCOTLAND

    Nov 1, 2008, 00:00

  • PIN11 COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND

    Nov 1, 2008, 00:00

  • PMS5 PREVALENCE OF FIBROMYALGIA IN GERMANY

    Nov 1, 2008, 00:00

  • MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS- RESULTS FROM THE PHASE 3 GO-RAISE STUDY

    Nov 1, 2008, 00:00

  • AR3 TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PND4 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION- A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2008, 00:00

  • PCN95 POLICY-MAKING FOR EXPENSIVE INNOVATIVE DRUGS IN FRANCE- ECONOMIC IMPACT AND INFLUENCE ON STAKEHOLDERS! BEHAVIOURS OF POTENTIAL DECISIONS ABOUT TAXANES

    Nov 1, 2008, 00:00

  • PCV116 THE ANALYSIS OF STATINS USAGE IN CROATIA DURING THE FIVE-YEAR PERIOD

    Nov 1, 2008, 00:00

  • PMS62 DISCONTINUATION RATE OF THE IST AND IIND ANTI-TUMOR NECROSIS FACTORTHERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY

    Nov 1, 2008, 00:00

  • PMC5 A MISSING DATATHRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA- DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS

    Nov 1, 2008, 00:00

  • PND20 MEASURING THE IMPACT OF NARCOLEPSY ON QUALITY OF LIFE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCN62 ECONOMIC BURDEN OF TOXICITIES ASSOCIATED WITH SALVAGE TREATMENT IN ADVANCED AND METASTATIC BREAST CANCER

    Nov 1, 2008, 00:00

  • PDB58 PREDICTION MODEL FOR BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENT

    Nov 1, 2008, 00:00

  • PCV106 PATIENT OUTCOMES AND HEALTH ECONOMICS ASSOCIATED WITH THE USE OF OCTYLCYANOACROLATE TOPICAL SKIN ADHESIVE IN CABG SURGERY

    Nov 1, 2008, 00:00

  • PIH15 HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS WITH THE PRADER-WILLI SYNDROME

    Nov 1, 2008, 00:00

  • PRS36 WILLINGNESS TO PAY FOR CAREGIVERS OF PEDIATRIC ASTHMATIC PATIENTS IN KOREA

    Nov 1, 2008, 00:00

  • PDB1 THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS- A MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PCV67 CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PMC54 THE RIGOUR, FLEXIBILITY AND EASE OF IMPLEMENTATION OF SYSTEMATIC SEARCH STRATEGIES-DOWE NEED AN INDUSTRY STANDARD METHODOLOGY?

    Nov 1, 2008, 00:00

  • PMS26 COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPENTIBIA FRACTURES IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCN110 STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PSS2 EFFECTIVENESS OF THE RESTOR MULTIFOCAL INTRAOCULAR LENS (IOL) IN CATARACT AND PRESBYOPIA SURGERIES IN TWO EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCV48 ENHANCING SYNCOPE DIAGNOSTICS- COST-EFFECTIVENESS ANALYSIS OF AN IMPLANTABLE LOOP RECORDER STRATEGY VERSUS THE STANDARD OF CARE

    Nov 1, 2008, 00:00

  • PCV26 TREATING TO LOWER LDL-C TARGETS- ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED FOR REGIONAL HEALTH ECONOMIES IN ENGLAND, SCOTLAND, WALES AND NORTHERN IRELAND

    Nov 1, 2008, 00:00

  • MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES- DETERMINISTIC AND PROBABILISTIC APPROACHES

    Nov 1, 2008, 00:00

  • PDB67 PATIENT-CENTERED OUTCOMES IN THE ECONOMIC EVALUATION OF TYPE 2 DIABETES TREATMENT- A SYSTEMATIC REVIEW OF MODELING METHODS

    Nov 1, 2008, 00:00

  • PHP36 PERFORMANCE OF YOUR 5-STAR HOSPITALS

    Nov 1, 2008, 00:00

  • PIN41 DEVELOPING AN ECONOMIC MODEL OF GRAM COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) FOR INPATIENT AND OUTPATIENT TREATMENT SETTINGS

    Nov 1, 2008, 00:00

  • PCV112 STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC STROKE- RESULTS FROM THE STROKE ANALYZER DATABASE

    Nov 1, 2008, 00:00

  • PMS58 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ)- USE OF A TOOL TO AID DIAGNOSIS

    Nov 1, 2008, 00:00

  • PMC36 AN INVESTIGATION OF FACTORIAL STRUCTURE OF SF-36V2 IN THE US GENERAL POPULATION-THE APPLICATION OF CONFIRMATORY FACTOR ANALYSIS THROUGH STRUCTURAL EQUATION MODELLING

    Nov 1, 2008, 00:00

  • PDB37 IS INSULIN GLARGINE A COST-EFFECTIVE OPTION FOR TREATMENT OF PATIENTS NA AND AGE BELOW 65YEARS IN COMPARISON TO NPH AND PREMIX IN POLAND?

    Nov 1, 2008, 00:00

  • PG110 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE- AN ECONOMIC EVALUATION BASED ON THE PODIUM RANDOMISED CONTROLLED TRIAL

    Nov 1, 2008, 00:00

  • PCN70 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE REGIMEN-AN ECONOMIC EVALUATION BASED ON OBSERVATIONAL DATA

    Nov 1, 2008, 00:00

  • PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PSS23 TOPICAL TACROLIMUS FOR THE TREATMENT OF A TOPIC DERMATITIS- A SYSTEMATIC REVIEW WITH META-ANALYSES

    Nov 1, 2008, 00:00

  • MD1 HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND

    Nov 1, 2008, 00:00

  • PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FORWOMEN WITH HER2 METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND

    Nov 1, 2008, 00:00

  • PDB34 MONITORING OF TREATMENT COSTS AFTER REIMBURSEMENT DECISION- SOMATOSTATIN ANALOGUES FOR ACROMEGALY

    Nov 1, 2008, 00:00

  • PCN54 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN THE UNITED KINGDOM (UK)

    Nov 1, 2008, 00:00

  • PCV105 STATIN PRESCRIBING IN THE CITY OF ZAGREB (2001-2006) AND THEIR ROLE IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS

    Nov 1, 2008, 00:00

  • PCN79 HEALTH STATE PREFERENCE STUDY MAPPING THE CHANGE OVER THE COURSE OF THE DISEASE PROCESS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

    Nov 1, 2008, 00:00

  • PMC4 FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS IN THE SOCIAL SECURITY INSTITUTION OF TURKEY

    Nov 1, 2008, 00:00

  • PSY4 EPIDEMIOLOGY OF IDIOPATHICTHROMBOCYTOPENIC PURPURA IN BELGIUM ASSESSED USING HOSPITAL RECORDS

    Nov 1, 2008, 00:00

  • PSY18 COST-EFFECTIVENESS OF FENTANYL ITS (IONSYSTM) IN POST-OPERATIVE PAIN MANAGEMENT- A FINNISH HOSPITAL PERSPECTIVE ANALYSIS

    Nov 1, 2008, 00:00

  • PSY6 PREDICTING FACTORS FOR METABOLIC SYNDROME FOR US ADOLESCENTS AGE 12-17

    Nov 1, 2008, 00:00

  • PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS- RESULTS FROMTHREE PHASE 3 STUDIES

    Nov 1, 2008, 00:00

  • PMC33 THE ROLE OF RANKING DATA IN HEALTHVALUATION

    Nov 1, 2008, 00:00

  • PDB66 INSULIN GLARGINE UTILIZATION IN REAL-LIFE-EFFICACY OF A REGIMEN BASED ON INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES PREVIOUSLY ON NPH INSULIN IN CLINICAL PRACTICE IN SPAIN

    Nov 1, 2008, 00:00

  • MH7 PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY- A MIXED METHODS APPROACH TO CAPTURING THE PATIENTS PERSPECTIVE

    Nov 1, 2008, 00:00

  • HT3 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTHTECHNOLOGY APPRAISAL SYSTEMS- NICE, SMC, CADTH AND PBAC

    Nov 1, 2008, 00:00

  • MD3 COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEMS PERSPECTIVE IN AUSTRIA

    Nov 1, 2008, 00:00

  • PSY60 PREDICTING FACTORS FOR METABOLIC SYNDROME AMONG US ADOLESCENTS 12-17YEARS OF AGE

    Nov 1, 2008, 00:00

  • PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION- A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2008, 00:00

  • PDB41 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A UK SETTING

    Nov 1, 2008, 00:00

  • PG134 PATIENT PREFERENCES FOR CROHNS DISEASE MAINTENANCE THERAPY- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PCN81 CROSS-CULTURAL ADAPTATION INTO SPANISH AND ITEM REDUCTION OF THE UCLA-PROSTATIC CANCER INDEX (UCLA-PCI)- A SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) QUESTIONNAIRE FOR PROSTATIC CANCER

    Nov 1, 2008, 00:00

  • HP3 TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US CLAIMS DATABASE

    Nov 1, 2008, 00:00

  • PDB2 IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM INSULIN NPHTO INSULIN GLARGINE- A RETROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2008, 00:00

  • PSS27 COST-EFFECTIVENESS OF THREE INTRA-OCULAR LENSES AFTER CATARACT SURGERY IN THE NETHERLANDS- RESTOR, ARRAY-SA40 AND A MONOFOCAL

    Nov 1, 2008, 00:00

  • PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS

    Nov 1, 2008, 00:00

  • PG121 REDUCTION OF WORK PRODUCTIVITY ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD) AND RELATED COSTS

    Nov 1, 2008, 00:00

  • PMS51 MAJOR DETERMINANTS OF EUROQOL (EQ-5D) IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON A LARGE JAPANESE COHORT IORRA

    Nov 1, 2008, 00:00

  • PMH2 DIRECT AND INDIRECT TREATMENT EFFECTS ON SLEEP DISTURBANCE IN GENERALIZED ANXIETY DISORDER- A STATISTICAL MEDIATION MODEL ANALYSIS

    Nov 1, 2008, 00:00

  • PCV88 IMPACT OF SINGLE-PILL VS. 2-PILL AMLODIPIN/ATORVASTATIN TREATMENT ON COMPLIANCE- A CZECH PILOT PROJECT ON MEDICATION ADHERENCE

    Nov 1, 2008, 00:00

  • PIN48 VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2008, 00:00

  • PMH60 DETERMINANTS OF PRESCRIPTION IN PRIMARY CARE- PROFILE OF PATIENTS PRESCRIBED NEWER ANTIDEPRESSANTS IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PHP57 INAPPROPRIATE SEDATION IN ICUS- EVIDENCE FROM THE LITERATURE

    Nov 1, 2008, 00:00

  • PMS11 PREVALENCE OF FIBROMYALGIA IN RUSSIA- EARLY RESULTS

    Nov 1, 2008, 00:00

  • PDB10 COMPREHENSIVE LIPID PROFILE AMONGTYPE 2 DIABETES MELLITUS (T2DM) POPULATION IN SPAIN. RECAP-DM SPANISH COHORT STUDY

    Nov 1, 2008, 00:00

  • PCN2 EFFICACY OF LEUPRORELIN 3.75MG COMPARED TO 7.5MG IN THE TREATMENT OF PROSTATE CANCER- SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2008, 00:00

  • CN8 AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE

    Nov 1, 2008, 00:00

  • PCN99 AVAILABILITY AND SPATIAL DISTRIBUTION OF ONCOLOGY SPECIFIC RESOURCES IN GREECE

    Nov 1, 2008, 00:00

  • PIN49 INTERNATIONAL DEVELOPEMENT OF A NEW HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO HIV/AIDS-PROQOL HIV STUDY

    Nov 1, 2008, 00:00

  • PHP58 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE- THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA

    Nov 1, 2008, 00:00

  • PCV90 THE CONTRIBUTION OF THE MEASUREMENT OF TREATMENT ACCEPTABILITY TO UNDERSTAND PATIENTS ADHERENCE TO LONG-TERM TREATMENTS. RESULTS FROM A FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA- A COMMUNITY-PHARMACY NETWORK DEDICATED TO PHARMAC ...

    Nov 1, 2008, 00:00

  • PCV7 CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION-A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PMH45 A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY

    Nov 1, 2008, 00:00

  • PND13 ALZHEIMERS DISEASE PRESCRIPTION MEDICATION COSTS- 2004-2005

    Nov 1, 2008, 00:00

  • PMS20 IMPACT OF MEDICATION NON-COMPLIANCE AND NON-PERSISTENCE ON PHARMACOECONOMIC EVALUATIONS IN OSTEOPOROSIS

    Nov 1, 2008, 00:00

  • PMC39 WHAT DOES ACCEPTABILITY MEAN FOR PATIENTS AND HOW SHOULD IT BE MEASURED? QUALITATIVE STEPS FOR THE DEVELOPMENT OF A NEW MEASUREMENT INSTRUMENT IN PHARMACIES

    Nov 1, 2008, 00:00

  • PCV74 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUSTHROMBOEMBOLISM IN PATIENTS UNDERGOINGTOTAL HIP ORTOTAL KNEE REPLACEMENT SURGERY

    Nov 1, 2008, 00:00

  • PDB21 COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING

    Nov 1, 2008, 00:00

  • CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?- FINDINGS FROM, AND IMPLICATIONS OF, ONTARIOS EVIDENCE-BASED HTA PROCESS

    Nov 1, 2008, 00:00

  • PMS21 COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE

    Nov 1, 2008, 00:00

  • PMC24 SELF-ASSESSED HEALTH STATUS IN POLAND- EQ-5D FINDINGS FROM POLISH VALUATION STUDY

    Nov 1, 2008, 00:00

  • PMH37 SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW- RESULTS OF A QUANTITATIVE PATIENT SURVEY

    Nov 1, 2008, 00:00

  • MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS- THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PIN39 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PRS7 THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN SPAIN- AN ECOMIC MODELTO ESTIMATE BUDGET IMPACT CONSEQUENCES OF INTRODUCING BECLOMETHASONE/FORMOTEROL

    Nov 1, 2008, 00:00

  • PCN49 COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPIES FOR PROSTATE CANCER IN THE UK

    Nov 1, 2008, 00:00

  • DB4 COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PG118 DIRECT MEDICAL COSTS OF CROHNS DISEASE IN SPAIN- A MARKOV MODEL

    Nov 1, 2008, 00:00

  • PCN111 A STRUCTURED REVIEW OF STUDIES ON HEALTH-RELATED QUALITY OF LIFE IN KIDNEY CANCER, HEPATOCELLULAR CARCINOMA AND LEUKEMIA

    Nov 1, 2008, 00:00

  • PIN17 COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR

    Nov 1, 2008, 00:00

  • PMC45 WHAT PROPORTION OF DISEASES ARE QALYS AN IRRELEVANT MEASURE FOR?

    Nov 1, 2008, 00:00

  • PSY20 THE COST EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE NHS IN SCOTLAND

    Nov 1, 2008, 00:00

  • PDB7 LONGTERM HEALTH OUTCOMES IN NEWLY DIAGNOSED TREATMENT NA VE TYPE 2 DIABETES PATIENTS INITIATED WITH BIPHASIC INSULIN ASPART IN CHINA- DATA FROM THE IMPROVE STUDY

    Nov 1, 2008, 00:00

  • PCV38 EXTENDED PROPHYLAXIS OF VENOUSTHROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY- A PHARMACOECONOMIC STUDY

    Nov 1, 2008, 00:00

  • PCN4 EFFICACY OF OPIOIDS IN THE TREATMENT OF BREAKTHROUGH CANCER PAIN- A BAYESIAN MIXED TREATMENT COMPARISON

    Nov 1, 2008, 00:00

  • PIN43 DIFFERENCE IN HEALTH CARE UTILIZATION IN EUROPE BETWEENTREATMENT-NAVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTSWHO FAILED PRIOR THERAPY

    Nov 1, 2008, 00:00

  • PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST- ODDS SOLUTION TO RELATIVE RISK FALLACIES

    Nov 1, 2008, 00:00

  • PSS48 HOSPITAL DERMATOLOGY CONSULTATION TYPES- A FRENCH ASSESSMENT

    Nov 1, 2008, 00:00

  • PCV30 COST-EFFECTIVENESS ANALYSIS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) FOR ABDOMINAL AORTIC ANEURYSM (AAA) IN SPAIN

    Nov 1, 2008, 00:00

  • PUK4 PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN ITALY

    Nov 1, 2008, 00:00

  • PMC41 METHODOLOGICAL ISSUES IN THE LITERATURE ON COSTS OF NON-COMPLIANCE IN CHRONIC DISEASES

    Nov 1, 2008, 00:00

  • PSY53 SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD

    Nov 1, 2008, 00:00

  • PMS33 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN SPAIN

    Nov 1, 2008, 00:00

  • PCN51 POTENTIAL ECONOMIC AND HEALTH IMPACT OF GENOMICS AND PROTEOMICSTECHNOLOGY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

    Nov 1, 2008, 00:00

  • PHP49 ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTHTECHNOLOGY ASSESSMENT AGENCIES (HTA)

    Nov 1, 2008, 00:00

  • PSS44 A TOPIC DERMATITIS PSORIASIS- CROSS-EVALUATION OF QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PUK3 THE COST ADVANTAGE OF INCREASING THE USE OF PERITONEAL DIALYSIS IN TURKEY

    Nov 1, 2008, 00:00

  • PCV108 RISK AND COSTS OF THE FIRST HYPERTENSION-ASSOCIATED EVENT, COMPLIANCE AND PERSISTENCE IN NAVE HYPERTENSIVE PATIENTS AFTER INITIATING MONOTHERAPY

    Nov 1, 2008, 00:00

  • PMS67 HEALTH GAINS FOREGONE DUETO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS- THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS

    Nov 1, 2008, 00:00

  • PHP14 THE COMPETITIVE ACQUISITION PROGRAM (CAP)- WHERE IS IT AFTER TWO YEARS?

    Nov 1, 2008, 00:00

  • PRS2 RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN

    Nov 1, 2008, 00:00

  • PMC50 THE SUITABILITY OF VISUAL ANALOGUE SCALES (VAS) FOR COLLECTING PATIENT-REPORTED OUTCOMES (PRO) DATA FROM INTERNATIONAL SETTINGS

    Nov 1, 2008, 00:00

  • PMH19 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA IN NORWAY

    Nov 1, 2008, 00:00

  • PUK14 A HEALTH ECONOMIC EVALUATION OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS (ESA) IN PATIENTS WITH RENAL FAILURE TREATED WITH HAEMODIALYSIS

    Nov 1, 2008, 00:00

  • PDB51 UNDERSTANDING AND ASSESSING THE IMPACT OF DIABETES TREATMENT ACROSS MEDICATION DELIVERY SYSTEMS

    Nov 1, 2008, 00:00

  • PMH40 PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY- RESULTS FROM ADORE STUDY IN FRANCE

    Nov 1, 2008, 00:00

  • PSS21 ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANY

    Nov 1, 2008, 00:00

  • PDB14 LARGE IMPACT OF ANTIDIABETIC DRUGTREATMENT AND HOSPITALIZATIONS ON ECONOMIC BURDEN OF DIABETES MELLITUS IN THE NETHERLANDS DURING 2000 TO 2004

    Nov 1, 2008, 00:00

  • PCN18 AN EVALUATION OF THE COST SAVINGS GENERATED WITH THE USE OF AN INTRA-OPERATIVE ASSAY FOR THE DETECTION OF METASTASES IN THE SENTINEL LYMPH NODES OF PATIENTS WITH BREAST CANCER

    Nov 1, 2008, 00:00

  • PUK1 CLINICAL ATTITUDES ON CHRONIC GRAFT DYSFUNCTION- THE ICEBERG STUDY

    Nov 1, 2008, 00:00

  • PIN31 COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR, TWO NEW HIV TREATMENTS FOR TREATMENT-EXPERIENCED PATIENTS

    Nov 1, 2008, 00:00

  • PMC42 PATIENT AND POPULATION HEALTH-STATE VALUES ARE COMPARABLEWHEN DERIVED BY ELEMENTARY MEASUREMENT METHODS

    Nov 1, 2008, 00:00

  • PND11 EPILEPSY COST OF ILLNESS IN THE U.S. PRIVATELY INSURED

    Nov 1, 2008, 00:00

  • PHP43 GREEK HOSPITALS SUPPLY CHAIN MANAGEMENT

    Nov 1, 2008, 00:00

  • EE6 COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK

    Nov 1, 2008, 00:00

  • PSY36 EUROPEAN ECONOMIC EVALUATION OF OROS HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN

    Nov 1, 2008, 00:00

  • PSS33 THE COST OF UVEITIS TREATMENT IN FRANCE- A ONE-YEAR RETROSPECTIVE ANALYSIS

    Nov 1, 2008, 00:00

  • CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND

    Nov 1, 2008, 00:00

  • PMH21 COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA- 12 MONTH DATA FROM CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PCV86 COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2008, 00:00

  • PHP20 THE EFFECT OF THE INTRODUCTION OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITALWARDS IN HUNGARY

    Nov 1, 2008, 00:00

  • PMC25 IS THE EQ-5D QUESTIONNAIRE A PREDICTOR OF MORTALITY AND HOSPITALIZATION IN A GENERIC ELDERLY POPULATION?

    Nov 1, 2008, 00:00

  • PIN40 MANAGEMENT AND COST ASSOCIATED WITH NON-PERMANENT CATHETER-RELATED BACTERAEMIA CAUSED BY MICROORGANISMS GRAM-POSITIVES IN SPANISH HOSPITALS SETTINGS

    Nov 1, 2008, 00:00

  • PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PND17 ONE-YEAR EXPENSES FOR THE PHARMACOLOGICAL MANAGEMENT OF EPILEPSY WITHIN OUTPATIENT SETTING OF MONTENEGRO- RATIONAL OR NOT?

    Nov 1, 2008, 00:00

  • PCN25 COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN EARLY HER-2 POSITIVE BREAST CANCER PATIENTS- THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM CASE

    Nov 1, 2008, 00:00

  • PRS28 HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS OF A SURVEY IN 5 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PG11 THE DEVELOPMENT AND PERFORMANCE OF MODELS TO PREDICT RISK OF LIVER DISEASE DIAGNOSIS FOLLOWING LIVER FUNCTION TESTING IN PRIMARY CARE

    Nov 1, 2008, 00:00

  • PHP23 CHARACTERISTICS OF UTILIZATION OF PRIMARY CARE OF GENERAL PRACTITIONERS IN COUNTY BARANYA IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND

    Nov 1, 2008, 00:00

  • PG123 QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS WITH ULCERATIVE COLITIS IN REMISSION VS. MILD/MODERATE AND SEVERE RELAPSE- FINDINGS FROM THE PODIUM STUDY

    Nov 1, 2008, 00:00

  • PG138 RESULTS OF ALEGRIA, A REAL LIFE EVALUATION OF GERD IMPACT OF SYMPTOM ASSESSMENT IN BELGIUM

    Nov 1, 2008, 00:00

  • PND7 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PSS32 COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION GLAUCOMA MEDICATIONS BRIMONIDINE/TIMOLOL AND DORZOLAMIDE/TIMOLOL IN 10 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCN30 COST-EFFECTIVENESS OF APREPITANT IN PATINENTS RECEIVING ANTIEMETIC PROPHYLAXIS FOR HIGHLY EMETOGENIC CHEMOTHERAPY IN HUNGARY

    Nov 1, 2008, 00:00

  • PSS4 RESTOR VERSUS ACRILISA ND-YAG LASER INCIDENCE RATE COMPARISON ONE YEAR AFTER SURGERY

    Nov 1, 2008, 00:00

  • PMS14 NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY- A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PMS15 LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND-A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PMH48 TELEPHONE HOTLINE AS AN ADJUNCT TO CONTINUING CARE FOR ADOLESCENTS TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER

    Nov 1, 2008, 00:00

  • PCN90 DEVELOPMENT OF AN EFFECTIVE HOME PALLIATIVE CARE SYSTEM ADOPTING A MULTIDISCIPLINARYTEAM APPROACH-SATISFACTION OF THE PATIENTS FAMILY FOR THE DOMICILIARY PALLIATIVE CARE 'OKAYAMA' MODEL

    Nov 1, 2008, 00:00

  • PMH11 DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE- THE BUDGET IMPACT OF ILLEGAL DRUGS

    Nov 1, 2008, 00:00

  • PCN15 A COST-EFFECTIVENESS ANALYSIS OF IXABEPILONE FOR BREAST CANCER AT ATERTIARY CANCER CENTER

    Nov 1, 2008, 00:00

  • PND9 WITHIN-TRIAL COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE COMPARED TO STANDARD-OF-CARE IN THE SCHIZOPHRENIA TRIAL OF ARIPIPRAZOLE (STAR)

    Nov 1, 2008, 00:00

  • PHP7 COMPARING THE ACTUAL HOSPITAL COST OF A PATIENT WITH OESOPHAGEAL CANCERTO NORMATIVE DRG REIMBURSEMENT

    Nov 1, 2008, 00:00

  • PSS31 ACUTE OTITIS MEDIA- A MAJOR SOURCE OF PRODUCTIVITY LOSS

    Nov 1, 2008, 00:00

  • CN4 YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUETO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR CARCINOGENESIS-UNITED STATES, 2003

    Nov 1, 2008, 00:00

  • PUK9 COST OF OVERACTIVE BLADDER IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PDB24 A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE

    Nov 1, 2008, 00:00

  • PCN28 COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

    Nov 1, 2008, 00:00

  • PIN33 COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR

    Nov 1, 2008, 00:00

  • PCV73 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR- ACUTE INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN EMERGENCY SETTING

    Nov 1, 2008, 00:00

  • PMS17 THE ECONOMIC IMPLICATIONS OF ACHIEVING TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PMC2 HASTHE QUALITY OF RANDOMISED CONTROLLED TRIALS INCREASED WITH TIME- AN ANALYSIS OF DATA FROM 5 SYSTEMATIC REVIEWS?

    Nov 1, 2008, 00:00

  • PCV63 CO-MORBIDITY AND DIRECT COSTS ACCORDING THE CARDIOVASCULAR RISK LEVEL IN A SPANISH POPULATION SETTING

    Nov 1, 2008, 00:00

  • PIH2 ONE DAY NATIONAL SURVEY ON PREVALENCE OF MALE SEXUAL DYSFUNCTION, AMONG MEN CONSULTING UROLOGISTS

    Nov 1, 2008, 00:00

  • PMC34 METHODOLOGIES FOR ASSESSING AND DEMONSTRATING DATA SATURATION IN QUALITATIVE INQUIRY SUPPORTING PATIENT-REPORTED OUTCOMES RESEARCH

    Nov 1, 2008, 00:00

  • PHP21 THE EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY

    Nov 1, 2008, 00:00

  • PMC32 METHODS FOR ADDRESSING USE OF PRO INSTRUMENTS IN THE SAME LANGUAGE FOR DIFFERENT COUNTRIES- BEST PRACTICE GUIDELINES FOR DECISION-MAKING AND TRANSLATION OR ADAPTATION

    Nov 1, 2008, 00:00

  • PIN8 PATIENT FLOW PATHWAY FOR PATIENTS ADMITTED TO CRITICAL CARE UNITS WITH A SEVERE BACTERIAL INFECTION IN ENGLAND

    Nov 1, 2008, 00:00

  • AR1 PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PHP38 COST-EFFECTIVENESS OF PREVENTION- OPPORTUNITIES FOR PUBLIC HEALTH POLICY IN THE NETHERLANDS?

    Nov 1, 2008, 00:00

  • CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PHP2 CONSUMERS PERCEPTIONS OF DRUG EFFECTIVENESS AND PRICES IN GREECE

    Nov 1, 2008, 00:00

  • PSY57 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE NUMBER OF HOSPITAL ADMISSIONS FOR IMMUNE THROMBOCYTOPENIC PURPURA AND ITS ECONOMIC BURDEN IN FRANCE

    Nov 1, 2008, 00:00

  • PMH18 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN LONG-TERM TREATMENT OF SCHIZOPHRENIA IN TURKEY

    Nov 1, 2008, 00:00

  • PIN50 A REVIEW OF THE FACTORS AFFECTING PUBLIC FUNDING OF VACCINES

    Nov 1, 2008, 00:00

  • PDB15 COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND

    Nov 1, 2008, 00:00

  • PUK13 EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION- RESULTS OF ECONOMIC EVALUATION

    Nov 1, 2008, 00:00

  • PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE

    Nov 1, 2008, 00:00

  • PDB12 ASSOCIATION BETWEEN HYPOGLYCEMIA EPISODES AND CHANGES IN THE SULPHONYLUREA TREATMENT PATTERN IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS. RECAP-DM SPANISH COHORT STUDY

    Nov 1, 2008, 00:00

  • PCV121 LIPID MANAGEMENT OF HIGH RISK PATIENTS IN THE OUTPATIENT SETTING IN GERMANY- RESULTS OF DYSIS-GERMANY

    Nov 1, 2008, 00:00

  • PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP)-ARE ADDED THE RAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?

    Nov 1, 2008, 00:00

  • PHP53 EXPANDINGTHE PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI)- MEASURES GROUPS AND REGISTRY-BASED REPORTING

    Nov 1, 2008, 00:00

  • PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

    Nov 1, 2008, 00:00

  • PG135 PATIENT PREFERENCES FOR CROHNS DISEASE FLARE-UP THERAPY- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PMH15 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM/DIVALPROEX IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

    Nov 1, 2008, 00:00

  • PCV98 MODELLING THE EFFECT OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) ON CAPACITY AND PRODUCTIVITY OF CORONARY DIAGNOSTIC FACILITIES IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PMH57 SECOND GENERATION ANTIPSYCHOTICS AND HOSPITALIZATION IN BIPOLAR DISORDER- A CLAIMS DATA ANALYSIS

    Nov 1, 2008, 00:00

  • PDB16 THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA) IN TYPE 2 DIABETES IN POLAND

    Nov 1, 2008, 00:00

  • PCV61 INFLUENCE THE CO-MORBIDITY AND DIRECT COSTS OF STROKETO POPULATION SETTING AND IN CLINICAL PRACTICE

    Nov 1, 2008, 00:00

  • PMH24 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ADULT DEPRESSED MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PMS31 OSTEOARTHRITIS AND JOB ABSENTEEISM COSTS- EVIDENCE FROM U.S. NATIONAL SURVEY DATA

    Nov 1, 2008, 00:00

  • PMH28 THE ECONOMICS OF SCHIZOPHRENIA IN GERMANY AND THE POTENTIAL OF LONG ACTING SECOND GENERATION DEPOT TREATMENT

    Nov 1, 2008, 00:00

  • PMS27 COST CONSEQUENCE ANALYSIS OF RITUXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN ISRAEL

    Nov 1, 2008, 00:00

  • PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE 'ANTI-AGING-MEDICINE' FIELD- RESULTS FROM A SYSTEMATIC HORIZON SCANNING

    Nov 1, 2008, 00:00

  • PCN56 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN SPAIN

    Nov 1, 2008, 00:00

  • PDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PDB44 TREATMENT COMPLIANCE AND ILLNESS KNOWLEDGE IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES

    Nov 1, 2008, 00:00

  • PND24 CANTHE CHQ-PF50 BE USED TO MONITOR CHANGES IN BEHAVIORAL AND EMOTIONAL FUNCTIONING IN CHILDREN TREATED FOR EPILEPSY?

    Nov 1, 2008, 00:00

  • PMH5 COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PCN48 COST-MINIMIZATION ANALYSIS OF XELOXVERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL

    Nov 1, 2008, 00:00

  • PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PSY58 RETROSPECTIVE ANALYSIS OF FACTORVIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER RECOMBINANT B DOMAIN-DELETED OR FULL-LENGTH FACTOR VIII

    Nov 1, 2008, 00:00

  • PMH12 BUDGET IMPACT OF GENERIC ANTIPSYCHOTIC SUBSTITUTION-A DATABASE ANALYSIS IN GERMANY

    Nov 1, 2008, 00:00

  • PCV58 COSTS OF CORONARY ARTERY DISEASE (CAD) IN POLAND

    Nov 1, 2008, 00:00

  • PCV71 COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT A TRIAL FIBRILLATION IN SPAIN

    Nov 1, 2008, 00:00

  • PSY51 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS

    Nov 1, 2008, 00:00

  • PHP32 COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT

    Nov 1, 2008, 00:00

  • PSS20 SENSITIVE SKINS IN ITALY- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY

    Nov 1, 2008, 00:00

  • CV1 WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS?

    Nov 1, 2008, 00:00

  • PCN98 RACIAL DIFFERENCES IN MEDICATION-RELATED HEALTH CARE COSTS AND SERVICE UTILIZATION IN HORMONE RECEPTOR POSITIVE PRIMARY BREAST CANCER PATIENTS

    Nov 1, 2008, 00:00

  • OR1 EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS

    Nov 1, 2008, 00:00

  • PMH46 PATIENT PREFERENCES IN ADHD-DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PMC31 VALUING EQ-5D WITH TIME TRADE-OFF FOR THE POLISH POPULATION

    Nov 1, 2008, 00:00

  • CN7 MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER- THE CASE OF PARTICLE THERAPY

    Nov 1, 2008, 00:00

  • PSY40 BURDEN OF FIBROMYALGIA TO THE UK NATIONAL HEALTH SERVICE (NHS)

    Nov 1, 2008, 00:00

  • PSS36 THE DESCRIPTIVE EPIDEMIOLOGY AND OUTCOME OF HOSPITALISATIONS FOR PSORIASIS IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PMC23 WHAT IS POLITICIANS WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENTVALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES

    Nov 1, 2008, 00:00

  • PND3 ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND INPATIENT EVENTS)

    Nov 1, 2008, 00:00

  • MS3 POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PMS30 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN FRENCH PATIENTS

    Nov 1, 2008, 00:00

  • PG114 A HYPOTHETICAL ROAD MAPTO REDUCE ACID RELATED DISEASES COSTS MANAGEMENT

    Nov 1, 2008, 00:00

  • PSY37 HEALTH AND ECONOMIC CONSEQUENCES OF PATHOGEN TRANSMISSION RISK IN THE TREATMENT OF HAEMOPHILIA A WITH FACTOR VIII

    Nov 1, 2008, 00:00

  • PCV43 MODELED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE LIPID TARGETSWHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH SIMVASTATIN, ROSUVASTATIN, AND ATORVASTATIN

    Nov 1, 2008, 00:00

  • PSY56 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY AMONG HEMOPHILIA PATIENTS WITH INHIBITORS

    Nov 1, 2008, 00:00

  • PSY16 THE ECONOMIC IMPACT OF DIFFERENT STRATEGIES OF MANAGING RARE DISEASES WITH HIGH TREATMENT COSTS- THE CASE OF USING ACTIVATED RECOMBINANT FACTORVII IN SEVERE BLEEDS IN ACQUIRED HAEMOPHILIA PATIENTS

    Nov 1, 2008, 00:00

  • PSY11 EONOMIC EVALUATION OF ETANERCEPT COMPARED TO NO SYSTEMIC THERAPY IN THE MANAGEMENT OF LESS SEVERE CHRONIC PLAQUE PSORIASIS IN THE UK

    Nov 1, 2008, 00:00

  • PMS1 COGNITIVE IMPAIRMENT IN PATIENTS WITH FIBROMYALGIA SYNDROME AS ASSESSED BY THE MINIMENTAL STATE EXAMINATION

    Nov 1, 2008, 00:00

  • PIH11 COST OF INSOMNIA IN PATIENTS OVER 54 YEARS IN SWEDEN

    Nov 1, 2008, 00:00

  • PSS56 PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA

    Nov 1, 2008, 00:00

  • PCN94 COST-EFFECTIVENESS AND PREFERENCE FOR FOLLOW-UP SCENARIOS FOLLOWING BREAST CANCER

    Nov 1, 2008, 00:00

  • PMS32 THE DIRECT HEALTH CARE COSTS OF OSTEOARTHRITIS- EVIDENCE FROM US NATIONAL SURVEY DATA

    Nov 1, 2008, 00:00

  • QL4 PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA

    Nov 1, 2008, 00:00

  • PSY24 MANAGEMENT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM- A COST OF ILLNESS STUDY

    Nov 1, 2008, 00:00

  • PMH23 THE ECONOMIC EFFECTS OF FASTER TITRATION AND LOWER RELAPSE RATE OF QUETIAPINE XR COMPARED TO QUETIAPINE IR-THE ECONOMICVALUE OF A NEW DRUG FORMULATION

    Nov 1, 2008, 00:00

  • PUK5 COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS

    Nov 1, 2008, 00:00

  • PSS51 SCORING AND PSYCHOMETRIC VALIDATION OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)

    Nov 1, 2008, 00:00

  • PMH31 A GPRD-BASED COMPARISON OF SECOND-LINE ANTIDEPRESSANT THERAPY WITH ESCITALOPRAM AND VENLAFAXINE

    Nov 1, 2008, 00:00

  • PHP24 USE OF THE AMCP FORMAT IN THE U.S.-A NATIONAL SURVEY OF HEALTH PLANS

    Nov 1, 2008, 00:00

  • PSY30 HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY- IS INITIAL DOSING A SIGNIFICANT FACTOR?

    Nov 1, 2008, 00:00

  • PMH58 BUDGET CONSTRAINTS AS A MAJOR CAUSE FOR UNDERTREATMENT OF PATIENTS SUFFERING FROM ALZHEIMERS DISEASE IN GERMANY- A COMPARATIVE PANEL SURVEY OF GENERAL PRACTIONERS AND NEUROLOGISTS

    Nov 1, 2008, 00:00

  • PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION- A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE

    Nov 1, 2008, 00:00

  • PMC52 LINGUISTIC VALIDATION OF THE FRENCH FOR CANADA WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTHVERSION (WPAI-GH)

    Nov 1, 2008, 00:00

  • PMS2 DIAGNOSIS OF OSTEOPOROSIS BY DUAL X-RAY AND LASER (DXL) DENSITOMETRY-A HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PIN15 COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV- RESULTS OF A DECISION MODEL WITH LOCAL DATA

    Nov 1, 2008, 00:00

  • PSS52 SCORING AND PSYCHOMETRIC PROPERTIES OF THE EYE-DROP SATISFACTION QUESTIONNAIRE (EDSQ)

    Nov 1, 2008, 00:00

  • PCV84 HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007- FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)

    Nov 1, 2008, 00:00

  • PCV9 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF IRBESARTANVS. CANDESARTAN

    Nov 1, 2008, 00:00

  • PCV1 THE ROLE OF LDL-LEVELS IN INITIATING STATIN TREATMENT

    Nov 1, 2008, 00:00

  • PG122 ASSESSING THE PATIENT-REPORTED IMPACT OF USING BOWEL CLEANSING PREPARATIONS

    Nov 1, 2008, 00:00

  • DB1 ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO IN TYPE 1 DIABETES IN THE UNITED KINGDOM- A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS

    Nov 1, 2008, 00:00

  • PCV27 MODELING THE FISCAL IMPACT OF USING PERFLUTREN LIPID MICROSPHERES (PLM) FOR FOLLOW-UP ECHOCARDIOGRAPHIC IMAGING

    Nov 1, 2008, 00:00

  • PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENTTHERAPY WITH GENOTROPIN IN HYPOPITUITARY ADULT PATIENTS

    Nov 1, 2008, 00:00

  • PIN21 ECONOMICAL EVALUATION OF ETRAVIRINE IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS BASED ON DUET TRIALS

    Nov 1, 2008, 00:00

  • PHP52 EVALUATION OF CURRENT ASSESSMENTS OF WORLDWIDE AGENCIES FOR HEALTHTECHNOLGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PDB42 COST-UTILITY OF INSULIN GLARGINE COMPARED TO PRE MIX IN TYPE 2 FROM PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2008, 00:00

  • PDB65 A COMPARISON OF DIABETES KNOWLEDGE AMONG RESIDENTS IN BANGKOK AND OTHER CENTRAL PROVINCES OF THAILAND

    Nov 1, 2008, 00:00

  • PCV15 CORONS STUDY- EXAMPLE OF STATINS IMPACT ON ALL CAUSE MORTALITY IN THE ELDERLY

    Nov 1, 2008, 00:00

  • PSS3 VISION WITH RESTOR, ARRAY SA40 AND A MONOFOCAL INTRA-OCULAR LENS (IOL) AFTER CATARACT SURGERY

    Nov 1, 2008, 00:00

  • PDB8 BURDEN OF DIABETES AND ASSOCIATED TREATMENT PATTERNS IN EUROPE- A COMPARISON OF SIX COUNTRIES

    Nov 1, 2008, 00:00

  • PCV47 ECONOMIC EVALUATION OF AN ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAM

    Nov 1, 2008, 00:00

  • PHC4 COST-EFFECTIVENESS OF HARMONIC SCALPEL USE VERSUS CONVENTIONALTOTAL THYROIDECTOMY

    Nov 1, 2008, 00:00

  • PND16 INDIRECT COSTS OF ALZHEIMERS DISEASE IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PSS22 FINAL EVALUATION OF THE PERSISTENCE DEGREE OF PATIENTS IN FIRST-LINE MONOTHERAPY ANTIGLAUCOMATOUS TREATMENT IN SPAIN

    Nov 1, 2008, 00:00

  • PMC56 THE TRANSFERABILITY OF ECONOMIC EVALUATIONS. VALIDATING THE MODEL OF WELTE

    Nov 1, 2008, 00:00

  • PCV21 EFFECT OF WEATHER CONDITIONS ON THE MORTALITY OF HEART ATTACKS IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN57 PALLIATIVE CARE FOR CANCER PATIENTS IN BRAZIL- A COST-OF-ILLNESS STUDY

    Nov 1, 2008, 00:00

  • PSY64 PATIENT-REPORTED OUTCOMES (PROS) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY

    Nov 1, 2008, 00:00

  • PDB62 IMPACT OF INSURANCE PAYMENT SYSTEMS ON QUALITY OF CARE AND HEALTH CARE SERVICE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES

    Nov 1, 2008, 00:00

  • PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY- A COSTEFFECTIVENESS ANALYSIS

    Nov 1, 2008, 00:00

  • PDB45 SELF-MANAGEMENT AND PATIENT PERCEPTIONS OF CARE IN RELATION TO HEALTH AND COST-RELATED OUTCOMES IN TYPE 2 DIABETES- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCN74 A SERVICE EVALUATION TO COMPARE SECONDARY CARE RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

    Nov 1, 2008, 00:00

  • PSY43 THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED OUTCOMES MEASURED BY THE EUROQOL (EQ-5D)

    Nov 1, 2008, 00:00

  • PG129 INDIVIDUAL AND SOCIETAL PREFERENCE SCORES BOTH IDENTIFY ACTIVE INFLAMMATORY BOWEL DISEASE (IBD) IN GERMANY

    Nov 1, 2008, 00:00

  • PDB3 SWITCHING FROM PREMIXED INSULIN TO INSULIN GLARGINE-BASED REGIMEN IMPROVES GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 1 ORTYPE 2 DIABETES- A RETROSPECTIVE PRIMARY CARE-BASED ANALYSIS

    Nov 1, 2008, 00:00

  • PIN34 COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY

    Nov 1, 2008, 00:00

  • PCN106 PROSTATE CANCER DIAGNOSIS IN SPAIN- HOW IS IT PERFORMED? HOW MUCH DOES IT COST FOR SPANISH NHS?

    Nov 1, 2008, 00:00

  • PCV96 ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE

    Nov 1, 2008, 00:00

  • PIN26 COST-EFFECTIVENESS OF TREATMENT WITH PEGASYS/COPEGUS IN HIV/HCV CO-INFECTED PATIENTS IN PORTUGAL

    Nov 1, 2008, 00:00

  • PCV53 DECISION ANALYTIC MODEL FOR GENETIC TESTING IN THE MANAGEMENT OF WARFARIN ANTICOAGULATION TREATMENT FOR HOSPITALIZED PATIENTS

    Nov 1, 2008, 00:00

  • PCV35 COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA

    Nov 1, 2008, 00:00

  • PCV49 COST-EFFECTIVENESS OF ATORVASTATIN 80 MGVS GENERIC SIMVASTATIN 20 TO 40 MG IN SECONDARY PREVENTION IN SPAIN

    Nov 1, 2008, 00:00

  • PMS24 THE COST-EFFECTIVENESS OF SEQUENTIAL USE OF ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PHP28 A COMPARISON OF HIGH-COST HEALTH CARE PROGRAMS AVAILABLE IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PG132 CORRELATION BETWEENTHE SEVERITY OF UPPER GASTROINTESTINAL (GI) SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE GREEK PRIMARY CARE SETTING

    Nov 1, 2008, 00:00

  • CV3 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES

    Nov 1, 2008, 00:00

  • PMS60 QUALITATIVE STEPS FOR THE DEVELOPMENT OF A QUESTIONNAIRE ASSESSING THE BURDEN OF FIBROMYALGIA ON PATIENTS DAILY LIVES

    Nov 1, 2008, 00:00

  • PIN42 DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSS ASSOCIATED WITH VENOUS LEG ULCER

    Nov 1, 2008, 00:00

  • PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

    Nov 1, 2008, 00:00

  • PDB40 COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE DM1 FROM A PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2008, 00:00

  • PCN1 THIRD-GENERATION AROMATASE INHIBITORS VS TAMOXIFEN IN THE TREATMENT OF EARLY AND ADVANCED BREAST CANCER- A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2008, 00:00

  • MO3 COMPARING METHODS OF DATA SYNTHESIS- UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL

    Nov 1, 2008, 00:00

  • PDB31 THE COST OF TYPE 2 DIABETES MELLITUS IN CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PIN4 A MARKOV MODELTO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY

    Nov 1, 2008, 00:00

  • PRS29 SOCIOECONOMIC ANALYSIS OF SMOKERS PROFILE WHO INTENDS TO QUIT

    Nov 1, 2008, 00:00

  • PMS38 COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA

    Nov 1, 2008, 00:00

  • PDB54 PSYCHOLOGICAL INSULIN RESISTANCE (PIR)- PATIENT AND PHYSICIAN BELIEFS IMPACTING DIABETES MANAGEMENT

    Nov 1, 2008, 00:00

  • PCV14 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS-GREECE

    Nov 1, 2008, 00:00

  • PND2 HUNTINGTONS DISEASE- WHERE HAVEWE BEEN?

    Nov 1, 2008, 00:00

  • PMC62 UNIVERSAL TRANSLATION AND NEUROPSYCHOLOGICAL COMPARISONS OF PATIENTS FROM US-MEXICO BORDER REGION AND SPAIN

    Nov 1, 2008, 00:00

  • PMH35 COST ANALYSIS OF THE TRENDS IN HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN FROM 1980-2004

    Nov 1, 2008, 00:00

  • PRS17 COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF MODERATE AND SEVERE EXACERBATIONS OF COPD IN POLAND IN 2007

    Nov 1, 2008, 00:00

  • PCN53 COST IMPACT OF CAPECITABINE THERAPY INTRODUCTION IN BREAST CANCER PATIENTS

    Nov 1, 2008, 00:00

  • PMH44 LINGUISTIC VALIDATION, SENSITIVITY AND SPECIFICITY OF THE SCALE 'DEPRESSION IN THE MEDICALLY ILL-18'

    Nov 1, 2008, 00:00

  • PHP39 LINKING HOSPITAL ADMISSION DATA INTO PRIMARY CARE RECORDS WITHIN THE GENERAL PRACTICE RESEARCH DATABASE

    Nov 1, 2008, 00:00

  • PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY- A WILLINGNESS TO PAY STUDY

    Nov 1, 2008, 00:00

  • QL9 DEVELOPMENT AND VALIDATION OF AN ELETRONIC VERSION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI)

    Nov 1, 2008, 00:00

  • PRS31 A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPE

    Nov 1, 2008, 00:00

  • PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN

    Nov 1, 2008, 00:00

  • PCN27 ECONOMIC EVALUATION OF A TOBACCO CESSATION PROGRAM AT A MAJOR CANCER CENTER

    Nov 1, 2008, 00:00

  • PIN19 PHARMACOECONOMIC EVALUATION OF PARENTERAL ITRACONAZOLE USE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKISH SETTING

    Nov 1, 2008, 00:00

  • PSS10 SENSITIVE SKIN IN EUROPE- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCV82 CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY

    Nov 1, 2008, 00:00

  • PCN80 PATIENT REPORTED QUALITY OF LIFE IN CANCER PATIENTS ON OPIOID THERAPY IS INFLUENCED BY CONSTIPATION

    Nov 1, 2008, 00:00

  • PMH33 COST-UTILITY ANALYSIS OF DULOXETINE VERSUS VENLAFAXINE IN THE MANAGEMENT OF MAJOR DEPRESSION IN PORTUGAL

    Nov 1, 2008, 00:00

  • PSY14 COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES III AND IV- TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER ...

    Nov 1, 2008, 00:00

  • PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS- FINDINGS FROM THE PHOENIX I TRIAL

    Nov 1, 2008, 00:00

  • PIN12 COST-EFFECTIVENESS OF CERVARIX, A PROPHYLACTIC CERVICAL CANCERVACCINE, IN SPAIN

    Nov 1, 2008, 00:00

  • PUK6 COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION (SNM) FOR PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PIH19 THE ASSOCIATION OF BODY MASS INDEX ON HEALTH RELATED QUALITY OF LIFE IN THE GENERAL ADULT POPULATION IN ENGLAND

    Nov 1, 2008, 00:00

  • PIN10 THE ECONOMIC IMPACT OF LOWER HIV PREVALENCE ESTIMATES

    Nov 1, 2008, 00:00

  • PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

    Nov 1, 2008, 00:00

  • PDB5 GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE OR DETEMIR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- AN ANALYSIS OF ELECTRONIC MEDICAL RECORDS

    Nov 1, 2008, 00:00

  • MD4 UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY- COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY

    Nov 1, 2008, 00:00

  • PSS8 A TOPIC DERMATITIS IN CHILDHOOD- WHAT 'DERMATOLOGICAL FUTURE' FOR THESE CHILDREN?

    Nov 1, 2008, 00:00

  • PCV34 COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED MAGNETIC RESONANCE (MR) ANGIOGRAPHY FOR THE PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD) IN KOREA

    Nov 1, 2008, 00:00

  • PDB36 COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA

    Nov 1, 2008, 00:00

  • PCN59 ECONOMIC BURDEN OF TREATING VIN AND VAIN 2/3 IN GERMANY

    Nov 1, 2008, 00:00

  • PMC20 QUANTITATIVE APPROACH TO DETERMINE THE EFFECT OF SEGMENTATION ON REVENUE GENERATION, POSITIONING AND PRICING OF PHARMACEUTICALS

    Nov 1, 2008, 00:00

  • PMS34 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PIH6 SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES IN OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE

    Nov 1, 2008, 00:00

  • PG136 SELF-DIAGNOSIS AND HEALTH SEEKING BEHAVIOUR OF WOMEN FOR MINOR BOWL AILMENTS IN A LARGE REPRESENTATIVE UNITED KINGDOM (UK) SAMPLE POPULATION

    Nov 1, 2008, 00:00

  • PMS9 PREVALENCE OF FIBROMYALGIA IN PORTUGAL

    Nov 1, 2008, 00:00

  • PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION-A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND

    Nov 1, 2008, 00:00

  • PDB43 ADDING INSULIN GLARGINE TO ORALTHERAPY IN PATIENTS WITHTYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN

    Nov 1, 2008, 00:00

  • PCV109 PRESCRIPTION DRUG INSURANCE AND EX ANTE MORAL HAZARD

    Nov 1, 2008, 00:00

  • PMS41 COST-EFFECTIVENESS OF CELECOXIB COMPARED TO CONVENTIONAL NSAIDS AND NSAIDPPI COMBINATION THERAPY IN RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PIN46 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH VENOUS LEG ULCER

    Nov 1, 2008, 00:00

  • PCN38 COST-EFFECTIVENESS OF EXTENDED ADJUVANT TREATMENT WITH LETROZOLE IN SWEDEN

    Nov 1, 2008, 00:00

  • PG117 REALWORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHNS DISEASE

    Nov 1, 2008, 00:00

  • PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT- ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM

    Nov 1, 2008, 00:00

  • PMH51 DECLINE IN DEPRESSION TREATMENT PERSISTS AFTER FDA ANTIDEPRESSANTWARNINGS

    Nov 1, 2008, 00:00

  • PSY22 PROCESS STUDY- A 6-MONTHS COST-CONSEQUENCE ANALYSIS IN CHRONIC PAIN FROM THE SPANISH PERSPECTIVE

    Nov 1, 2008, 00:00

  • PDB49 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES

    Nov 1, 2008, 00:00

  • PCV32 ECONOMIC EVALUATION OF ATORVASTATIN AND ROSUVASTATIN USING HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL WITH UP-TITRATION OF DRUG DOSES TO OBTAIN THERAPEUTIC TARGETS FOR LDL-CHOLESTEROL

    Nov 1, 2008, 00:00

  • PCN87 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC- PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRASTUMOR STATUS

    Nov 1, 2008, 00:00

  • PND1 INCIDENCE OF INJURY AND COST OF CARE FOR PATIENTS SEEKING EMERGENT CARE FOR EPILEPSY IN A UNITED STATES MANAGED CARE SETTING

    Nov 1, 2008, 00:00

  • PHP22 COMPARATIVE ANALYSIS OF HOSPITAL BED CAPACITITES OF OLD (EU-15) AND NEW (EU-12) MEMBERSTATES OF THE EUROPEAN UNION

    Nov 1, 2008, 00:00

  • PRS37 RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER DRUGTHERAPY

    Nov 1, 2008, 00:00

  • PSS37 IDENTIFYING NON COMPLIANT GLAUCOMA PATIENTS USING THE EDSQ, A QUESTIONNAIRE MEASURING SATISFACTION AND COMPLIANCE OF GLAUCOMA TREATMENT

    Nov 1, 2008, 00:00

  • PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY

    Nov 1, 2008, 00:00

  • PRS25 THE PUBLICS WILLINGNESS TO PAY FOR A QALY IN THAILAND

    Nov 1, 2008, 00:00

  • PMH56 PATTERNS OF FIRST VISITS TO PSYCHIATRIC CLINICS IN TAIWAN- A NATIONWIDE STUDY, 2006

    Nov 1, 2008, 00:00

  • PCV94 PREDICTORS OF HEALTH STATUS CHANGE AMONG PATIENTS TREATED WITH A CALCIUM ANTAGONISTOR AN ATENOLOL-LED HYPERTENSION STRATEGY IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)

    Nov 1, 2008, 00:00

  • PHC7 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN CANADA

    Nov 1, 2008, 00:00

  • PCV89 THE COST EFFECTIVENESS OF PERSISTENCE TO ANTIHYPERTENSIVE TREATMENT

    Nov 1, 2008, 00:00

  • PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES-RESULTS OF A PILOT STUDY

    Nov 1, 2008, 00:00

  • MH6 ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS- RESULTS FROM THE COMETA STUDY

    Nov 1, 2008, 00:00

  • PMC17 VALIDITY OF ELECTRONIC PRECRIPTION CLAIMS RECORDS- A COMPARISON OF ELECTRONIC PBM CLAIMS RECORDS WITH PHARMACY PROVIDER DERIVED RECORDS

    Nov 1, 2008, 00:00

  • PND12 COSTS OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PMC26 PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS AND MCS OF THE SF-36

    Nov 1, 2008, 00:00

  • PMS3 A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE VS OTHER THERAPUETIC OPTIONS IN THE TREATEMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PMH30 ANTIDEPRESSANT THERAPY DURING PREGNANCY- AN INSIGHT ON ITS POTENTIAL HEALTH CARE COSTS

    Nov 1, 2008, 00:00

  • PHP6 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 483 IN SPAIN- A POPULATION-BASED STUDY

    Nov 1, 2008, 00:00

  • PSY7 THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE ADULTS IN A MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSIS-RELATED HIP FRACTURES

    Nov 1, 2008, 00:00

  • PHP29 MICROCOSTING STUDY OF THE DAILY ICU COSTS IN THREE COUNTRIES

    Nov 1, 2008, 00:00

  • PRS3 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ADMINISTRATIVE HEATH SERVICES DATABASES

    Nov 1, 2008, 00:00

  • CV2 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A TRIAL FIBRILLATION-AF-QOL

    Nov 1, 2008, 00:00

  • PDB60 A COMPARISON OF THE MANAGEMENT OF SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES- SIMILARITIES, DIFFERENCES AND RESOURCE IMPLICATIONS

    Nov 1, 2008, 00:00

  • PCN86 SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)

    Nov 1, 2008, 00:00

  • PG13 PHARMACOECONOMIC ASSESSMENT OF LANREOTIDE IN THE MANAGEMENT OF POST-OPERATIVE DIGESTIVE FISTULAS

    Nov 1, 2008, 00:00

  • PHP1 PATIENTS PREFERENCES FOR AND PRICE ELASTICITY OF GENERIC AND BRANDED OVER-THE-COUNTER MEDICINES-AN ADAPTIVE CONJOINT ANALYSIS (ACA) APPROACH

    Nov 1, 2008, 00:00

  • PSY21 COST-MINIMIZATION ANALYSIS OF ORALVS. INTRAVENOUS FLUDARABINE (BENEFLUR) IN SPAIN

    Nov 1, 2008, 00:00

  • PDB59 TREATMENT PATTERNS AND GOAL ATTAINMENT FOR PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2008, 00:00

  • PDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE SECTOR IN SOUTH AFRICA

    Nov 1, 2008, 00:00

  • PMC16 EXPENSIVE DRUGS FOR RARE DISORDERS AND THE LOGIC OF COST-EFFECTIVENESS

    Nov 1, 2008, 00:00

  • PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER

    Nov 1, 2008, 00:00

  • PIH16 PSYCHOMETRIC PERFORMANCE OF THE CHILDRENS DERMATOLOGY QUALITY OF LIFE INDEX

    Nov 1, 2008, 00:00

  • PSS16 SENSITIVE SKINS IN GERMANY- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PIN1 A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS)

    Nov 1, 2008, 00:00

  • PMH25 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ELDERLY DEPRESSED MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PCN88 QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2008, 00:00

  • PMS35 RHEUMATOID ARTHRITIS COST STUDY RESULTS IN POLAND

    Nov 1, 2008, 00:00

  • PRS1 SMOKING, ASTHMA AND COPD IN ADULTS- A TOO FREQUENT RELATION

    Nov 1, 2008, 00:00

  • PCN61 INVASIVE FUNGAL INFECTION (IFI) IN PATIENTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)-TREATMENT COST FROM HOSPITAL PERSPECTIVE

    Nov 1, 2008, 00:00

  • PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PG19 THE COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS ESOMEPRAZOLE IN PEPTIC ULCER BLEEDING- A DECISION-TREE MODEL WITH SPANISH COSTS AND NEW CLINICAL DATA

    Nov 1, 2008, 00:00

  • PSY26 COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006

    Nov 1, 2008, 00:00

  • PND19 AT ALIZUMAB REDUCES RELAPSE-ASSOCIATED COSTS HOSPITALIZATIONS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

    Nov 1, 2008, 00:00

  • PSY8 BUDGET IMPACT ANALYSIS OF DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH BETATHALASSAEMIA IN VENETO REGION, ITALY

    Nov 1, 2008, 00:00

  • PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PCN6 MODELING LUNG AND BREAST CANCER INCIDENCE IN SPAIN- A ZERO INFLATED NEGATIVE BINOMIAL REGRESSION APPROACH

    Nov 1, 2008, 00:00
  • «
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148 (current)
  • 149
  • 150
  • »